Pages that link to "Q33830649"
Jump to navigation
Jump to search
The following pages link to Development of a safe live Leishmania vaccine line by gene replacement. (Q33830649):
Displaying 50 items.
- Genomic-scale prioritization of drug targets: the TDR Targets database (Q24635333) (← links)
- Host Cell Phenotypic Variability Induced by Trypanosomatid-Parasite-Released Immunomodulatory Factors: Physiopathological Implications (Q24796644) (← links)
- Molecular determinants and regulation of Leishmania virulence (Q24798781) (← links)
- Leishmania spp. Proteome Data Sets: A Comprehensive Resource for Vaccine Development to Target Visceral Leishmaniasis (Q26858852) (← links)
- Development of novel prime-boost strategies based on a tri-gene fusion recombinant L. tarentolae vaccine against experimental murine visceral leishmaniasis (Q28486287) (← links)
- A dual drug sensitive L. major induces protection without lesion in C57BL/6 mice (Q28539173) (← links)
- Live vaccination tactics: possible approaches for controlling visceral leishmaniasis (Q28542081) (← links)
- Control of malaria and other vector-borne protozoan diseases in the tropics: enduring challenges despite considerable progress and achievements (Q30565638) (← links)
- Molecular cloning, cell localization and binding affinity to DNA replication proteins of the p36/LACK protective antigen from Leishmania infantum (Q30657332) (← links)
- Identification of genes encoding arabinosyltransferases (SCA) mediating developmental modifications of lipophosphoglycan required for sand fly transmission of leishmania major (Q33187035) (← links)
- Mapping the antigenicity of the parasites in Leishmania donovani infection by proteome serology (Q33267301) (← links)
- Recent advances in identifying and validating drug targets in trypanosomes and leishmanias. (Q33542293) (← links)
- Infection with arginase-deficient Leishmania major reveals a parasite number-dependent and cytokine-independent regulation of host cellular arginase activity and disease pathogenesis (Q33566856) (← links)
- Leishmania major MPK7 protein kinase activity inhibits intracellular growth of the pathogenic amastigote stage (Q33585885) (← links)
- Functional and genetic evidence that nucleoside transport is highly conserved in Leishmania species: Implications for pyrimidine-based chemotherapy (Q33610259) (← links)
- Genetically modified organisms and visceral leishmaniasis (Q33647026) (← links)
- Biomarkers of safety and immune protection for genetically modified live attenuated leishmania vaccines against visceral leishmaniasis - discovery and implications (Q33659753) (← links)
- Identifying vaccine targets for anti-leishmanial vaccine development (Q33693899) (← links)
- Leishmania pifanoi amastigote antigen P-4: epitopes involved in T-cell responsiveness in human cutaneous leishmaniasis (Q33756069) (← links)
- Vaccination with a Leishmania infantum HSP70-II null mutant confers long-term protective immunity against Leishmania major infection in two mice models (Q33783745) (← links)
- Leishmaniasis Vaccine: Where are We Today? (Q33929859) (← links)
- Leishmaniasis: current status of vaccine development (Q33941719) (← links)
- Conditions influencing the efficacy of vaccination with live organisms against Leishmania major infection (Q33946585) (← links)
- Use of an attenuated leishmanial parasite as an immunoprophylactic and immunotherapeutic agent against murine visceral leishmaniasis (Q33998229) (← links)
- Subunit vaccination of mice against new world cutaneous leishmaniasis: comparison of three proteins expressed in amastigotes and six adjuvants (Q34003547) (← links)
- Heterologous expression of Trypanosoma cruzi trans-sialidase in Leishmania major enhances virulence (Q34004312) (← links)
- Heterogeneity of wild Leishmania major isolates in experimental murine pathogenicity and specific immune response (Q34008582) (← links)
- Live nonpathogenic parasitic vector as a candidate vaccine against visceral leishmaniasis (Q34033343) (← links)
- Development of vaccines against human parasitic diseases: tools, current status and perspectives (Q34074704) (← links)
- Visceral Leishmaniasis: Advancements in Vaccine Development via Classical and Molecular Approaches (Q34076804) (← links)
- Knockout of the dhfr-ts gene in Trypanosoma cruzi generates attenuated parasites able to confer protection against a virulent challenge (Q34105267) (← links)
- An update on antileishmanial vaccine candidates and prospects for a canine Leishmania vaccine (Q34346535) (← links)
- Pterin transport and metabolism in Leishmania and related trypanosomatid parasites (Q34534653) (← links)
- Deficiency of Leishmania phosphoglycans influences the magnitude but does not affect the quality of secondary (memory) anti-Leishmania immunity (Q34776215) (← links)
- Leishmania model for microbial virulence: the relevance of parasite multiplication and pathoantigenicity (Q35093068) (← links)
- In silico analysis of six known Leishmania major antigens and in vitro evaluation of specific epitopes eliciting HLA-A2 restricted CD8 T cell response. (Q35198753) (← links)
- Lipophosphoglycan is a virulence factor distinct from related glycoconjugates in the protozoan parasite Leishmania major. (Q35202576) (← links)
- Development of Vaccines against Visceral Leishmaniasis (Q35207606) (← links)
- Leishmania infantum HSP70-II null mutant as candidate vaccine against leishmaniasis: a preliminary evaluation (Q35427832) (← links)
- Present status of antileishmanial vaccines (Q35584883) (← links)
- Centrin gene disruption impairs stage-specific basal body duplication and cell cycle progression in Leishmania (Q35745876) (← links)
- Coinjection with CpG-containing immunostimulatory oligodeoxynucleotides reduces the pathogenicity of a live vaccine against cutaneous Leishmaniasis but maintains its potency and durability (Q35802037) (← links)
- Killed but metabolically active Leishmania infantum as a novel whole-cell vaccine for visceral leishmaniasis (Q35867177) (← links)
- Recent advances in vaccines for leishmaniasis (Q35873792) (← links)
- Intradermal Immunization of Leishmania donovani Centrin Knock-Out Parasites in Combination with Salivary Protein LJM19 from Sand Fly Vector Induces a Durable Protective Immune Response in Hamsters. (Q35890723) (← links)
- CD8(+) T cells in leishmania infections: friends or foes? (Q35927465) (← links)
- Adjuvants for Leishmania vaccines: from models to clinical application (Q36021357) (← links)
- Loss of virulence inLeishmania donovanideficient in an amastigote-specific protein, A2 (Q36561148) (← links)
- Leishmania donovani whole cell antigen delivered with adjuvants protects against visceral leishmaniasis in vervet monkeys (Chlorocebus aethiops). (Q36680084) (← links)
- Development of Leishmania vaccines: predicting the future from past and present experience (Q36700453) (← links)